The inaugural SciCafé event series —held at NYU Langone Health—brought together the insights and energy of an invitation only gathering of New York’s biotech and investment leaders. Featuring scientific talks from Henry Colecraft (Columbia University), Arvin Dar (Memorial Sloan Kettering), and Muzammal Hussain (NYU), along with a forward looking panel discussion, the event explored the breakthroughs and bottlenecks shaping the next generation of therapeutics.
In our first Whitepaper edition exclusively prepared for this event series, Scitaris maps the evolving landscape of Induced Proximity Therapeutics, with a spotlight on targeted protein degradation (TPD). Senior Consultant Marie Klimontova, PhD, examines the field’s dynamic shift toward molecular glues, the expanding role of antibody based degraders, and emerging modality innovations.
The whitepaper also highlights how TPD applications are rapidly moving beyond oncology—propelling BTK degraders to the forefront, unlocking opportunities in autoimmune and inflammatory diseases, and building confidence in CNS directed strategies. Looking ahead, we explore the next wave of induced proximity platforms—from RIPTACs and DUBTACs to extracellular degraders—and consider how these technologies may define future therapeutic paradigms.
To learn more, check out the official NYU event page here.
